Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company’s public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
COVID-19 related treatment and outcomes among COVID-19 ICU patients: A retrospective cohort study

Abdullah Assiri a,∗, Mir J. Iqbal a, Atheer Mohammed a, Abdulrhman Alsaleh a, Ahmed Assiri b, Adee Noor c, Redwan Nour d, Moteb Khobrani a

a Department of Clinical Pharmacy, College of Pharmacy, King Khalid University, Abha 62529, Saudi Arabia
b Department of Pharmacy Services, Asir Central Hospital, Abha 62529, Saudi Arabia
c Department of Information Technology, Faculty of Computing and Information Technology, King Abdulaziz University, Jeddah 80221, Saudi Arabia
d Department of Computer Science, Taibah University, Medina 42353, Saudi Arabia

ABSTRACT

Background: The COVID-19 pandemic remains an immediate and present concern, yet as of now there is still no approved therapeutic available for the treatment of COVID-19. This study aimed to investigate and report evidence concerning demographic characteristics and currently-used medications that contribute to the ultimate outcomes of COVID-19 ICU patients.

Methods: A retrospective cohort study was conducted among all COVID-19 patients in the Intensive Care Unit (ICU) of Asir Central Hospital in Saudi Arabia between the 1st and 30th of June 2020. Data extracted from patients’ medical records included their demographics, home medications, medications used to treat COVID-19, treatment durations, ICU stay, hospital stay, and ultimate outcome (recovery or death). Descriptive statistics and regression modelling were used to analyze and compare the results. The study was approved by the Institutional Ethics Committees at both Asir Central Hospital and King Khalid University.

Results: A total of 118 patients with median age of 57 years having definite clinical and disease outcomes were included in the study. Male patients accounted for 87% of the study population, and more than 65% experienced at least one comorbidity. The mean hospital and ICU stay was 11.4 and 9.8 days, respectively. The most common drugs used were tocilizumab (31.4%), triple combination therapy (45.8%), favipiravir (56.8%), dexamethasone (86.7%), and enoxaparin (83%). Treatment with enoxaparin significantly reduced the length of ICU stay (p = 0.04) and was found to be associated with mortality reduction in patients aged 50–75 (p = 0.03), whereas the triple regimen therapy and tocilizumab significantly increased the length of ICU stay in all patients (p = 0.01, p = 0.02 respectively).

Conclusion: COVID-19 tends to affect males more significantly than females. The use of enoxaparin is an important part of COVID-19 treatment, especially for those above 50 years of age, while the use of triple combination therapy and tocilizumab in COVID-19 protocols should be reevaluated and restricted to patients who have high likelihood of benefit.

© 2021 The Author(s). Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Introduction

Like many other countries, Saudi Arabia has been experiencing an outbreak of novel coronavirus disease 2019 (COVID-19) since the beginning of March [1–3]. COVID-19 rapidly became pandemic and is now considered a global health emergency. While it is most common for people with COVID-19 (40%) to develop only mild or moderate disease, approximately 15% develop severe disease requiring oxygen support [2,4–6]. As the pandemic evolves, it has been observed that severe cases might develop adverse outcomes quickly, resulting in a persistently increasing death rate [7,8]. Therefore, it is urgent to determine options for prevention and treatment to help identify patients with poor prognosis and to slow the spread of COVID-19. In Saudi Arabia, more than 522,000 COVID-19 cases were identified; and the Ministry of Health (MoH) along with other governmental agencies and organizations have taken all precautions and measurements to control the outbreak.

* Corresponding author.
E-mail address: aalabdullah@kku.edu.sa (A. Assiri).

https://doi.org/10.1016/j.jiph.2021.08.030
1876-0341/© 2021 The Author(s). Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
MoH has been providing monthly updated treatment protocols and medical approaches on how to manage COVID-19 patients. Identification of patients who are at higher risk of being infected with COVID-19 is an important preventive approach that allows extra caution to be applied before patients are infected, along with taking early steps and making clinical decisions after infection that slow the rapid progression of the disease and consequently save lives. Several studies have been performed and subsequently reported to describe the clinical characteristics of COVID-19 patients [1,2]. In addition to identifying risk factors to which are attributed an influence on a patient’s infection with COVID-19, several currently-used medications have shown promising evidence of relevance.

Given the novelty of this virus and the lack of an existing approved treatment, extensive efforts are underway to test and identify a safe and effective treatment. Most researchers’ efforts have been directed toward testing currently-used medications with minimum or even no evidence in COVID-19 management [5,9,10]. It’s not known yet whether these medications have any impact on a COVID-19 patient’s ultimate outcome. It’s possible that these medications might improve patient outcome and reduce time to recovery. Such information would provide important opportunities and hope for patients who are infected while on these medications. Moreover, it might give clinicians the opportunity to use medications associated with positive clinical outcomes in currently-developed COVID-19 management protocols.

The social healthcare system in the Kingdom is considered one of the key contributors towards containing the infection [1]. To meet clinical needs, a multi-disciplinary approach is required, and many COVID-19 management protocols have developed. However, there are limited studies available that have evaluated methods of therapeutic management; as a result, obvious knowledge gaps remain in this area. Our study was conducted to explore the association of risk factors and currently-used drugs for COVID-19 treatment with fatal outcomes and to determine the best available options to treat COVID-19 infection.

Patients and methods

Study design

We conducted a retrospective cohort study among all COVID-19 patients who presented to a tertiary care hospital in Asir Region, Saudi Arabia and were admitted to the Intensive Care Unit (ICU) between the 1st and 30th of June 2020. All patients diagnosed with COVID-19 by next-generation sequencing or real-time RT-PCR methods based on respiratory specimens and who had a definite outcome were included. The study used a single cohort design in light of the fact that the study hospital was the only tertiary care and designated hospital at the recruitment time for transfer of COVID-19 patients from other primary and secondary care regional hospitals. The study was approved by the Institutional Ethics Committee of King Khalid University (KKU-2020-01.01) and by the Ministry of Health Institutional Review Board Committee, Asir Region (REC-02-08-2020).

Data source

Data extracted from patients’ medical records included demographics, home medications, medications used to treat COVID-19, treatment duration for each COVID-19-related medication, ICU stay, hospital stay, and ultimate outcome (recovery or death). Patient management protocols, including national and international guidelines adopted by the hospital, were also noted for reference. Data integrity and privacy were ensured by all means: participants were assigned numeric identifiers, the database was password-protected, and access was restricted to selected investigators with completed confidentiality agreements.

Statistical analysis

Statistical analyses were conducted using SPSS (IBM® SPSS® Statistics 27) [11] and GraphPad Prism (RRID:SCR_002798) [12]. Continuous and categorical variables are presented as means (SD) and n (%), respectively. Descriptive statistics such as absolute numbers and percentages were used to summarize univariate characteristics. A binary logistic regression was conducted to examine whether potentially associated predictor variables had significant effects on the odds of the outcome variable, which was coded as 0 for death (reference category) and 1 for recovery. The significance level was set at 5%. Finally, a regression model was used to investigate the effect of all predictors on each of two variables: hospital stay days and ICU stay days. Variables were included in the analysis if was associated in at least 30 patients. With respect to COVID-19 treatment medications, a patient was considered treated with a particular agent if they received it for at least 50% of their hospital stay. Since mortality risk from COVID-19 infection might be affected by age, patients were stratified into age-based ranges (<25, 25–49, 50–75, >75) to account for mortality risk differences among different age groups.

Results

Study population and characteristics

From June 1, 2020 to June 30, 2020, 118 patients infected with COVID-19 were admitted and treated in the ICU; data from these patients were included in the final analysis. Patient characteristics are summarized and presented in Table 1. Of the study population, two patients were aged less than 25 years old, 41 between 25–49 years old, 64 between 50–75 years old, and 11 were >75 years old. Male patients accounted for 87% of the study population. Around 68.8% experienced at least one comorbidity, while the remainder had no comorbidity. The mean hospital and intensive care unit (ICU) stay was 11.4 and 9.8 days, respectively.

Treatment for patients infected with COVID-19

The patients received different treatment regimens for COVID-19 based on their respective situations and supporting published evidence during the study period. The predominant medications used to treat COVID-19 among the study population were tocilizumab, triple combination therapy (lopinavir/ritonavir, ribavirin, and interferon beta-1b), favipiravir, and dexamethasone, which were respectively received by 31.4%, 45.8%, 55.1%, 56.8%, and 86.7% of participants. Other medications used for COVID-19 treatment included: acyclovir, lopinavir, oseltamivir, azithromycin, budesonide, fludorocortisone, hydrocortisone, methylprednisolone, prednisolone, and hydroxychloroquine, as summarized in Table 1. None of our patients received Remdesivir and Baricitinib due to unavailability. Also, different antibiotics and antifungals were used empirically according to our antibiogram and institutional pneumonia management guidelines. The mean durations of treatment for agents mostly used in treating COVID-19 are illustrated in Fig. 1. With respect to supportive therapy, 83% of patients received enoxaparin for the duration of their hospitalization.
Table 1
Patient demographics.

| Characteristic                  | Total patients (N = 118) | %   |
|---------------------------------|--------------------------|-----|
| Age, mean (SD)                  |                          |     |
| <25                             | 56 (14.9)                |     |
| 25–49                           | 2                        | 1.7 |
| 50–75                           | 41                       | 34.7|
| >75                             | 64                       | 54.3|
| Gender                          |                          |     |
| Male                            | 103                      | 87  |
| Female                          | 15                       | 13  |
| Co-morbidities                  |                          |     |
| Yes                             | 81                       | 68.6|
| No                              | 37                       | 31.4|
| COVID-19-related treatment      |                          |     |
| Anti-viral                      |                          |     |
| Acyclovir                       | 3                        | 2.5 |
| Favipiravir                     | 67                       | 56.8|
| Lopinavir                       | 3                        | 2.5 |
| Oseltamivir                     | 10                       | 8.5 |
| Triple combination therapy      | 54                       | 45.8|
| Corticosteroids                 |                          |     |
| Budesonide                      | 23                       | 21.4|
| Dexamethasone                   | 93                       | 86.7|
| Fluorocortisone                 | 12                       | 11.2|
| Hydrocortisone                  | 14                       | 13.1|
| Methylprednisolone              | 12                       | 11.2|
| Prednisolone                    | 1                        | 0.9 |
| Other Medication                |                          |     |
| Enoxaparin                      | 99                       | 83.9|
| Hydroxychloroquine              | 6                        | 4.2 |
| Interferon                      | 65                       | 55.1|
| Tocilizumab                     | 37                       | 31.4|
| Intensive Care Unit stay (days), mean (SD) | 9.8 (7.2) |     |
| Hospital stay (days), mean (SD) | 11.4 (7.2)               |     |

Table 2
Results from evaluation of the effects of patient characteristics and treatments on mortality.

| Variable                   | N (%) | Deaths (%) | OR (95% CI) | p-Value |
|----------------------------|-------|------------|-------------|---------|
| Age                       |       |            |             |         |
| 25–49                     | 2 (1.7)| 0          | 0.56 (0.18, 1.67) | 0.30    |
| 50–75                     | 41 (34.7)| 2 (1.7) |             |         |
| >75                       | 64 (54.3)| 11 (9.3) |             |         |
| Gender                    |       |            |             |         |
| Female                    | 15 (12.7) | 1 (0.8) | 1.51 (0.17, 3.68) | 0.74    |
| Male                      | 103 (87.3)| 11 (9.3) |             |         |
| Comorbidity                |       |            |             |         |
| No                        | 45 (38.1)| 4 (3.4) | 0.89 (0.21, 3.46) | 0.87    |
| Yes                       | 73 (61.9)| 7 (5.5) |             |         |
| Cholecalciferol            |       |            |             |         |
| No                        | 28 (23.7)| 2 (1.7) | 0.57 (0.16, 2.22) | 0.60    |
| Yes                       | 90 (76.3)| 12 (10.2)|             |         |
| Zinc                      |       |            |             |         |
| No                        | 58 (49.2)| 4 (3.4) | 0.52 (0.08, 2.56) | 0.44    |
| Yes                       | 60 (50.8)| 10 (8.5)|             |         |
| Favipiravir                |       |            |             |         |
| No                        | 51 (43.2)| 3 (2.5) | 0.53 (0.07, 3.16) | 0.50    |
| Yes                       | 67 (56.8)| 11 (9.3)|             |         |
| Triple combination therapy |       |            |             |         |
| No                        | 64 (54.2)| 11 (9.3) | 2.20 (0.48, 12.22) | 0.32    |
| Yes                       | 54 (45.8)| 3 (2.5) |             |         |
| Dexamethasone              |       |            |             |         |
| No                        | 24 (20.3)| 2 (1.7) | 2.13 (0.19, 21.05) | 0.51    |
| Yes                       | 94 (79.7)| 12 (10.2)|             |         |
| Enoxaparin*                |       |            |             |         |
| No                        | 19 (16.1)| 5 (4.2) | 3.16 (0.70, 14.36) | 0.13    |
| Yes                       | 99 (83.9)| 9 (7.6) |             |         |
| Tocilizumab                |       |            |             |         |
| No                        | 81 (68.6)| 7 (5.9) | 0.38 (0.09, 1.40) | 0.15    |
| Yes                       | 37 (31.4)| 7 (5.9) |             |         |
| Azithromycin               |       |            |             |         |
| No                        | 27 (22.9)| 3 (2.5) | 0.74 (0.13, 3.35) | 0.71    |
| Yes                       | 91 (77.1)| 11 (9.3)|             |         |

* Enoxaparin was significantly associated with mortality reduction in patients 50–75 years old with \( p = 0.03 \) and OR of 7.90 (1.23, 63.85).

Fig. 1. Mean duration (days) of COVID-19 related treatments, hospital stay, and ICU stay.

Effect of patient characteristics and COVID-19 treatment on mortality

Several factors were assessed for effects on patient mortality, as reported in Table 2. These factors included age, gender, comorbidities, and treatment with any of: cholecalciferol, zinc, favipiravir, triple combination therapy, dexamethasone, enoxapar, interferon, tocilizumab, and azithromycin. All variables were incorporated in a binary regression model, and none of the assessed variables were found to be significantly associated with patient mortality. A subsequent analysis assessed the influence of these variables on patient mortality in the context of patient age group, as presented in Tables 1 and 2. Interestingly, treatment with enoxaparin was significantly associated with mortality reduction in patients aged 50–75 years old with \( p = 0.03 \) and odds ratio of 7.90, 95% CI 1.23, 63.85). No other variables were significantly associated with mortality in any age group.

Effect of patient characteristics and COVID-19 treatment on hospital and ICU stay

A multiple regression model was constructed to identify influencing factors and estimate their impacts on the hospital and ICU stays of COVID-19 patients during the study period. Among all variables, only the triple combination therapy significantly increased the length of hospital stay, with \( p = 0.02 \) (3.59, 95% CI 0.70, 6.49), as shown in Table 3. On the other hand, three factors were significantly associated with duration of ICU stay, as reported in Table 4. Enoxaparin use significantly reduced the length of ICU stay, with \( p = 0.04 \) (−3.73 95% CI −7.31, −0.14). Meanwhile, the triple combination therapy and tocilizumab both significantly increased length of ICU stay, with \( p = 0.01 \) (3.9, 95% CI 1.07, 6.72) and \( p = 0.02 \) (3.15, 95% CI 0.4, 5.89), respectively.
Table 3 Results from evaluation of the effects of patient characteristics and treatments on hospital stay length.

| Variable                                    | N (%)  | Estimate | p-Value |
|----------------------------------------------|--------|---------|---------|
| Age, mean (SD)                              | 56 (14.9) | 0.33 (–1.77, 2.44) | 0.75 |
| Gender                                       |        |         |         |
| Female                                       | 15 (12.7) | –2.28 (–6.15, 1.6) | 0.25 |
| Male                                         | 103 (87.3) | 2.34 (–0.61, 5.3) | 0.12 |
| Comorbidity                                  | 73 (61.9) | 1.98 (–0.67, 4.62) | 0.14 |
| Cholecalciferol                              | 90 (76.3) | 2.26 (–0.66, 6.17) | 0.26 |
| Zinc                                         | 60 (50.8) | 2.34 (–0.61, 5.3) | 0.12 |
| Favipiravir                                   | 67 (56.8) | 0.34 (–0.28, 3.53) | 0.84 |
| Triple combination therapy                   | 54 (45.8) | 3.59 (0.7, 6.49) | 0.02 |
| Dexamethasone                                | 94 (79.7) | 0.74 (–3.23, 4.72) | 0.71 |
| Enoxaparin                                   | 99 (83.9) | –2.03 (–5.71, 1.54) | 0.28 |
| Tocilizumab                                   | 37 (31.4) | 2.34 (–0.47, 5.15) | 0.1 |
| Azithromycin                                 | 91 (77.1) | –0.14 (–3.26, 2.98) | 0.93 |

Table 4 Results from evaluation of the effects of patient characteristics and treatments on Intensive Care Unit stay length.

| Variable                                    | N (%)  | Estimate | p-Value |
|----------------------------------------------|--------|---------|---------|
| Age, mean (SD)                              | 56 (14.9) | 0.47 (–1.59, 2.52) | 0.65 |
| Gender                                       |        |         |         |
| Female                                       | 15 (12.7) | –0.74 (–4.52, 3.04) | 0.7 |
| Male                                         | 103 (87.3) | 2.62 (0.26, 5.51) | 0.07 |
| Comorbidity                                  | 73 (61.9) | 1.77 (–0.81, 4.35) | 0.18 |
| Cholecalciferol                              | 90 (76.3) | 1.41 (–2.42, 5.23) | 0.47 |
| Zinc                                         | 60 (50.8) | 2.62 (0.26, 5.51) | 0.07 |
| Favipiravir                                   | 67 (56.8) | 1.77 (–1.35, 4.88) | 0.26 |
| Triple combination therapy                   | 54 (45.8) | 3.9 (1.07, 6.72) | 0.01 |
| Dexamethasone                                | 94 (79.7) | 0.17 (–3.71, 4.86) | 0.93 |
| Enoxaparin                                   | 99 (83.9) | –3.73 (–7.31, –0.14) | 0.04 |
| Tocilizumab                                   | 37 (31.4) | 3.15 (0.4, 5.89) | 0.02 |
| Azithromycin                                 | 91 (77.1) | –0.43 (–3.48, 2.61) | 0.78 |

Discussion

COVID continues to devastate and cripple countries across the world, with the magnitude of this devastation varying between countries. Evidence suggests that variation in the severity of the disease between populations can be attributed to differences in their demographic features, comorbidities, and immunological responses. In this retrospective cohort study, we investigated the contribution of clinical variables and COVID-19 treatment agents to the ultimate outcomes of ICU-admitted COVID-19 patients, specifically in the southern region of Saudi Arabia.

Our study population had a median age of 57 with the majority being 50–75 years of age. Male patients accounted for around 87% of participants, which is significantly higher than the proportion of females. Globally, trends in age distribution among COVID-19 patients have fluctuated as the pandemic progresses [13,14]. In March 2020, the U.S. Centers for Disease Control and Prevention reported that about half of COVID-19 patients were 55 or older, whereas in May 2020 nearly 70% of people who tested positive were younger than 60, with a median age of 48 [15]. Meanwhile, a national retrospective study conducted by Yousuf et al. in Saudi Arabia reported a median age of 36 years, with only 4.8% being age 14 or less and 5.9% being 60 or above [2]. However, the sex ratio of COVID-19 patients has been fairly consistent across diverse countries [2,4,6,7,15–18]. The higher infection rate prevalent among males in this study could be attributed to greater levels of exposure, as males are relatively more exposed to external environments than females. Additionally, more than 65% of the study population experienced at least one comorbidity. Finally, the mean hospital and ICU stay was around 11 and 10 days, respectively.

Numerous studies, including ours, have evaluated the association of mortality in COVID-19 with demographic and clinical variables like age, gender, and comorbidities. COVID-19 shows extremely strong risk stratification across age, socioeconomic factors, and clinical factors [4,6,16,18]. Increasing age, male sex, and acute illness severity are reported as associated with increased mortality risk [19]. In contrast with this trend, our results showed no significant association with patient mortality. This could be possibly due to early datasets like ours having limited sample size and assessments, wherein the association of mortality with these variables has yet to be completely established.

In terms of therapeutic management, the drugs most commonly used to treat patients in this study were tocilizumab, triple combination therapy, favipiravir, and dexamethasone. Globally, the most-commonly used medication varies from country to country according to each nation’s approved treatment protocol. A systematic review on therapeutic management of COVID-19 patients conducted by Tobaiqy et al. found corticosteroids and antivirals like lopinavir and oseltamivir to be most common agents used for COVID-19 treatment [10]. In this study, around 83% of participants received enoxaparin as a supportive therapy during their hospitalization, which practice has been adopted in light of several studies demonstrating high incidence of venous thromboembolic events (VTE) and arterial thromboembolism in COVID-19 patients due to a hypercoagulable state. Interestingly, we found enoxaparin use to be significantly associated with mortality reduction in patients aged 50–75 years old, which is congruent with multiple studies conducted around the world [5,20,21]. Additionally, enoxaparin use significantly reduced length of ICU stay in all patients, and subsequent analysis revealed this effect to be predominant in patients aged 50–75 years old. The age-group specificity of this effect could be explained by the limited sample numbers in other age groups. On the other hand, the risk of VTE and arterial thromboembolism increases with patient age; therefore, it is reasonable to find enoxaparin reduces risk significantly in this age group.

Tocilizumab (TCZ) has emerged as an alternative treatment for COVID-19 patients with cytokine storm, but there is insufficient evidence regarding its clinical efficacy and safety [22]. One meta-analysis of case series reports showed the use of tocilizumab in COVID-19 patients to be associated with a mortality rate of 21% [23]. Some interim recommendations consider tocilizumab to be an experimental medicine that should only be considered in severe cases [24]. In our study, around 31.4% of participants completed tocilizumab doses during their hospitalization. However, the use of tocilizumab significantly increased ICU stay and had no benefit in terms of mortality reduction. In light of the short study duration and limited evidence regarding the clinical safety and efficacy of tocilizumab in COVID-19 patients, the association between increased length of ICU stay and tocilizumab use is concerning. Therefore, this finding suggests that tocilizumab use should be restricted and limited until more research has generated evidence concerning its safety and efficacy in COVID-19 patients and the corresponding impact on hospital stay duration. Lastly, even though several studies had shown promising results from the use of triple combination therapy [25], our findings indicate that this treatment is associated with lengthening hospital and ICU stay. In the study conducted by Hung et al., patients who were randomized to the triple combination therapy did not receive interferon-beta as part of the regimen, which could explain the conflict between their findings and this study.

This study was undertaken during the ongoing pandemic, therefore faced limitations on direct and real-time access to patients that made prospective data collection difficult. It was also a single cohort study conducted in a limited population for a limited duration that studied retrospective data with limited demographic and clinical variables and measured definite outcomes. In light of the results and limitations of this study, a more inclusive and well-designed study is warranted that can generate conclusive evidence regard-
ing the various demographic and clinical variables that affect the management of COVID-19 patients in clinical practice.

In conclusion, the results of this study suggest that use of anticoagulants in treating COVID-19 reduces mortality in those 50 years and older and shortens length of ICU stay in all age groups. Additionally, the use of triple combination therapy or tocilizumab in COVID-19 treatment should be restricted to patients who could potentially benefit while experiencing minimum complications. Future studies with larger sample sizes are warranted to thoroughly evaluate the medications currently used for COVID-19 treatment and determine the best available treatment options for each patient.

**Funding**

The authors are thankful to the Deanship of Scientific Research at King Khalid University, Abha, Saudi Arabia, for supporting this research through grant number #GRP-288-40.

**Competing interests**

None declared.

**Ethical approval**

Not required.

**Acknowledgment**

The authors would like to acknowledge with great appreciation the Scientific Deanship at King Khalid University, Abha, Saudi Arabia for their administrative and technical support.

**References**

[1] Barry M, Al Amri M, Memish ZA. COVID-19 in the shadows of MERS-CoV in the Kingdom of Saudi Arabia. J Epidemiol Glob Health 2020; 10(1):1–3.
[2] AlSofayan YM, Althunayan SM, Khan AA, Hakawi AM, Assiri AM. Clinical characteristics of COVID-19 in Saudi Arabia: a national retrospective study. J Infect Public Health 2020; 13(7):520–5.
[3] Ahmad A, Alkhafary KM, Alrabiah Z, Alhossan A. Saudi Arabia, pharmacists and COVID-19 pandemic. J Pharm Policy Pract 2020:13:41.
[4] Zhang C, Zhang J, Wang B, Zhu X, Wang Q, Qiu S. Analysis of clinical characteristics and laboratory findings of 95 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a retrospective analysis. Respir Res 2020;21(1):74.
[5] Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost 2020;18(5):1094–9.
[6] Chen T, Wu D, Chen H, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ 2020;368:m1091.
[7] Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395(10229):1054–62.
[8] Zhou Y, Zhang Z, Tian J, Xiong S. Risk factors associated with disease progression in a cohort of patients infected with the 2019 novel coronavirus. Ann Palliat Med 2020;9(2):428–36.
[9] Venisse N. Potential drug-drug interactions associated with drugs currently proposed for COVID-19 treatment in patients receiving other treatments. Fun-dam Clin Pharmacol 2020.
[10] Toba-iq M, Qasheqy M, Al-Dahery S, et al. Therapeutic management of patients with COVID-19: a systematic review. JPrev Pract 2020;2(3):100061.
[11] IBM Corp. Released, Armonk, NY IBM SPSS statistics for windows, version 27.0: 2020.
[12] GraphPad Prism. https://www.graphpad.com/guides/prism/latest/user-guide/ citing_graphpad_prism.htm. [Accessed 23 October 2020].
[13] McMichael TM, Clark S, Popeoons S, et al. COVID-19 in a long-term care facility — King County, Washington, February 27–March 9, 2020. MMWR Morb Mortal Wkly Rep 2020;69(12):339–42.
[14] Garg S, Kim I, Whitaker M, et al. Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019 — COVID-NET, 14 states, March 1–30, 2020. MMWR Morb Mortal Wkly Rep 2020;69(15):458–64.
[15] Centers for Disease Control and Prevention. Coronavirus disease 2019 (COVID-19): cases in U.S. Atlanta, GA: US Department of Health and Human Services; 2020 https://www.cdc.gov/mortality/covid-19/cases-updates/cases-in-us.html.
[16] Goyal P, Choi JJ, Pinheiro LC, et al. Clinical characteristics of Covid-19 in New York City. N Engl J Med 2020;382(24):2372–4.
[17] Weiss P, Murdoch DR. Clinical course and mortality risk of severe COVID-19. Lancet 2020;395(10229):1014–5.
[18] Jordan RE, Adah P, Cheng KK. Covid-19: risk factors for severe disease and death. BMJ 2020;368:m1198.
[19] Van Singer M, Brahier T, Ngai M, et al. COVID-19 risk stratification algorithms based on iSTREMM-1 and IL-6 in emergency department. J Allergy Clin Immunol 2020.
[20] Pawlowski C, Venkatakrishnan AJ, Kirkup C, et al. Enoxaparin is associated with lower rates of thrombosis, kidney injury, and mortality than Unfractionated Heparin in hospitalized COVID patients. medRxiv 2020, 2020.2020.2020.20208025.
[21] Jin Y-H, Zhan Q-Y, Peng Z-Y, et al. Chemophrophylaxis, diagnosis, treatments, and discharge management of COVID-19: an evidence-based clinical practice guideline (updated version). Mil Med Res 2020;7(1):41.
[22] Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J. Tocilizumab treatment in COVID-19: a single center experience. J Med Virol 2020;92(7):814–8.
[23] Mohamed Hussain S, Ayesha Farhana S, Alwudayd O, et al. Efficacy of tocilizumab in Covid 19: a metaanalysis of case series studies. medRxiv 2020, 2020.2020.2012.20173682.
[24] Bergin C, Browne P, Murray P, et al. Interim Guidance for the use of tocilizumab in the management of patients who have severe COVID-19 with suspected hyperinflammation [v3.0].
[25] Hung I-F, Lung KC, Tso EY, et al. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet 2020;395(10238):1695–704.